Androgen Deprivation Therapy for Prostate Cancer — An Interview with Dr Rana R McKay (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr Rana R McKay, including the following topics:

• Overview of the current landscape of prostate cancer (0:00)
• Mechanism of action of androgen deprivation therapy (ADT) (3:51)
• Findings from the Phase III HERO study evaluating relugolix versus leuprolide for advanced prostate cancer (7:18)
• Real-world evidence regarding the use of relugolix (12:27)
• Adverse event profile associated with ADT (18:34)
• Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer who receives ADT at various timepoints of treatment and is currently on relugolix (21:46)
• Case: A man in his early 60s with high-risk locally advanced prostate cancer who receives various androgen receptor pathway inhibitors in addition to relugolix (28:06)

CME information and select publications